SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s President and CEO, Peter Altman, PhD., will present a corporate update, including recent progress toward milestones, at the H. C. Wainwright 27th Annual Global Investment Conference at the Lotte Palace Hotel in New York City.
Dr. Altman will present in person at 2:00 PM ET on Wednesday September 10, 2025. He will discuss the Company’s three clinical cell therapy programs for the treatment of ischemic heart disease and ongoing regulatory activities seeking FDA approval and Japan PMDA approval for CardiAMP® cell therapy for heart failure and its Helix™ transendocardial delivery catheter.
Dr. Altman will also detail the recent partnership to develop and commercialize Heart3D fusion imaging and the status of the nondilutive funding for the Company’s CardiALLO allogeneic mesenchymal stem cell program for the treatment of heart failure.
Dr. Altman will also be available for in person one-on-one meetings with investors.
The conference will be held from September 8-10, 2025 at the Lotte New York Palace Hotel. Dr. Altman’s presentation will be available for registered attendees via the conference platform. Conference attendees are invited to request one-on-one meetings via the conference portal, through their HCW representative, or directly with the Company through the investor contact email – This email address is being protected from spambots. You need JavaScript enabled to view it..
For more information about the H.C. Wainwright Global Investment Conference, please refer to the conference website at https://hcwevents.com/annualconference/.
Presentation Details:
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Marketing / Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
(650) 226-0120
| Last Trade: | US$2.04 |
| Daily Volume: | 18,967 |
| Market Cap: | US$11.830M |
August 13, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
